Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Ipilimumab in Melanoma Metastatic to the Brain
NCT02320058Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2015
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started Mar 2015; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02320058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320058.